Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 3, 1999, Pages 1116-1125

  Jones, David R ^a   Gorski, J Christopher ^a   Hamman, Mitchell A ^a   Mayhew, Bradley S ^a   Rider, Steven ^a   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; COMPLEMENTARY DNA; COUMARIN; CYTOCHROME P450; DIETHYLDITHIOCARBAMIC ACID; DILTIAZEM; FURAFYLLINE; MEPHENYTOIN; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; CATALYSIS; DEMETHYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CALCIUM CHANNEL BLOCKERS; CATALYSIS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; ENZYME INHIBITORS; HUMANS; KINETICS; METHYLATION; MICROSOMES, LIVER; NADP; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0032773854     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Ahonen J, Olkkola KT, Salmenperä M, Hynynen M and Neuvonen PJ (1996) Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 85:1246-1252.
2. Azie NE, Brater DC, Becker PA, Jones DR and Hall SD (1998) The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 64:369-377.
3. Backman JT, Olkkola KT, Aranko K, Himberg J-J and Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225.
4. Bensoussan C, Delaforge M and Mansuy D (1995) Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 49:591-602.
5. Bianchetti G, Regazzi M, Rondanelli R, Ascalone V and Morselli PL (1991) Bioavailability of diltiazem as a function of the administered dose. Biopharmaceut Drug Disp 12:391-401.
6. Boxenbaum HG, Riegelman S and Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokin Biopharm 2:123-148.
7. Brockmöller J, Heumayer HH, Wagner K, Weber K, Heinemeyer G, Kewitz H and Roots I (1990) Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 38:237-242.
8. Buters JTM, Schiller CD and Chou RC (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Biochem Pharmacol 46: 1577-1584.
9. Castle PJ, Merdink JL, Okita JR, Wrighton SA and Okita RT (1995) Human liver lauric acid hydroxylase activities. Drug Metab Disp 23:1037-1043.
10. Chiba M, Nishime JA and Linn JH (1995) Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275: 1527-1534.
11. Crespi CL, Penman BW, Steimel DT, Smith T, Yang CS and Sutter TR (1997) Development of a human lymphoblastoid cell line constitu lively expressing human CYP1B1 cDNA: Substrate specificity with model substrates and promutagens. Mutagen 12:83-89.
12. Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, Vandenbranden M, Wrighton SA and Wikel JH (1999) Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J Pharmacol Exp Ther 288:21-29.
13. Franklin MR (1977) Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacol Ther 2:227-245.
14. Franklin MR (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559-573.
15. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara Jr EM and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143.
16. Gorski JC, Jones DR, Wrighton SA and Hall SD (1994a) Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 48:173-182.
17. Gorski JC, Hall SD, Jones DR, VandenBranden M and Wrighton SA (1994b) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
18. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363-371.
19. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, VandenBranden M and Wrighton SA (1994) Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Disp 22:975-978.
20. Höglund P and Nilsson L-G (1989a) Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. Ther Drug Monit 11:543-550.
21. Höglund P and Nilsson L-G (1989b) Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. Ther Drug Monit 11:551-557.
22. Höglund P and Nilsson L-G (1989c) Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. Ther Drug Monit 11:558-566.
23. Jones DR, Gorski JC, Hamman MA and Hall SD (1996) Quantification of dextromethorphan and metabolites: A dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chrom B 678:105-111.
24. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561.
25. Laganière S, Davies RF, Carignan G, Foris K, Goemert L, Carrier K, Pereira C and McGilveray I (1996) Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther 60:257-264.
26. Leibbrandt DM and Day RO (1992) Cyclosporin and calcium channel blockers: An exploitable drug interaction? Med J Aust 157:296-297.
27. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA and Wolf CR (1990) Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 267:365-371.
28. Miners JO and Birkett DJ (1996a) The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol 27:245-249.
29. Miners JO and Birkett DJ (1996b) Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Meth Enz 272:139-145.
30. Montamat SC and Abernethy DR (1987) N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. Br J Clin Pharmacol 24:185-189.
31. Murray M and Butler AM (1996) Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J Pharmacol Exp Ther 279:1447-1452.
32. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Disp 23:154-158.
33. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2379-2385.
34. Pershing LK and Franklin MR (1982) Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics: A new class of agents. Xeno 12:687-699.
35. Powell PK, Wolf I and Lasker JM (1996) Identification of CYP4A11 as the major lauric acid ω-hydroxylase in human liver microsomes. Arch Biochem Biophy 335:219-226.
36. Rohlf FJ and Sokal RR (1981) Statistical Tables, 2nd ed, WH Freeman and Co, New York, pp 166-168.
37. Roos PH, Golub-Ciosk B, Kallweit P, Kauczinski D and Hanstein WG (1993) Formation of ligand and metabolite complexes as a means for selective quantitation of cytochrome P450 isozymes. Biochem Pharmacol 45:2239-2250.
38. Silverman RB (1988) Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology vol I, pp 3-30, CRC Press, Boca Raton, FL.
39. Sutton D, Butler AM, Nadlin L and Murray M (1997) Role of CYP3A4 in human hepatic diltilazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 28:294-300.
40. Toyosaki N, Toyo-Oka T, Natsume T, Katsuki T-A, Tateishi T, Yaginuma T and Hosoda S (1988) Combination therapy with diltiazem and nifedipine in patients with effort angina pectoris. Circulation 77:1370-1375.
41. Varhe A, Olkkola KT and Neuvonen PJ (1996) Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 59:369-375.
42. Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA and Wang X (1998) Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 287:381-388.
43. Waley SG (1985) Kinetics of suicide substrates. Biochem J 227:843-849.
44. Wedlund PJ and Wilkinson GR (1996) In vivo and in vitro measurement of CYP2C19 activity. Methods Enzymol 272:105-114.
45. Wrighton SA, Maurel P, Schuetz EG, Watkins PB, Young B and Guzelian PS (1985) Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450. Biochemistry 24:2171-2178.
46. Wrighton SA, Stevens JC, Becker GW and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophy 306:240-245.
47. Yeung PKF, Buckley SJ, Hung OR, Pollak PT, Barclay KD, Feng JDZ, Farmer PS and Klassen GA (1996) Steady-state plasma concentrations of diltiazem and its metabolites in patients and healthy volunteers. Ther Drug Monit 18:40-45.